Lyell Immunopharma
A leading biotechnology company is developing next-generation CAR T-cell therapies for cancer treatment, focusing on improving outcomes for patients with solid tumors and hematologic malignancies. The company is committed to innovative science, collaboration, and producing transformative therapies that resist exhaustion and have durable effects.
Headquarters
South San Francisco, California, United States
Company Size
201-500 employees
Founded
2018
Lyell is a fully integrated biopharmaceutical company developing next‑generation T‑cell reprogramming technologies to create durable CAR T‑cell therapies for hematologic malignancies and solid tumors. Their platform-driven approach spans discovery through clinical development, with active programs and trials such as the PiNACLE study for aggressive B‑cell non‑Hodgkin lymphoma and the recently acquired GCC‑targeted candidate LYL273. Lyell is patient‑focused, aiming to improve outcomes for cancers with significant unmet medical need.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Lyell Immunopharma.
HC Wainwright & Co. Maintains Lyell Immunopharma (LYEL) Neutral Recommendation
5 days ago
Senior Clinical Research Associate
Immatics
Hematology/Oncology Physician
The Provider Finder
(Sr.) Medical Science Liaison (MSL)
Aurabiosciences
Scientist, Non-Viral Gene Editing Platforms
Bristol Myers Squibb
Scientist, Cell Therapy Process Development (In Vivo CAR-T)
Bristol Myers Squibb
Clinical Trial Manager
Immatics